The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Overview

Hyperion Is A Prospective, Multicenter, Non-Interventional, Two-Cohort Study Collecting Primary Data In Patients With Locally Advanced Or Metastatic NSCLC Of Squamous Or Non-Squamous Histology After Prior Chemotherapy Being Treated With Atezolizumab In Routine Clinical Practice.

Full Title of Study: “The Effectiveness Of Atezolizumab Under Real-World Conditions In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 20, 2023

Interventions

  • Drug: Atezolizumab
    • Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).

Arms, Groups and Cohorts

  • Cohort 1
    • Participants who have demonstrated a lack of Clinical Benefit from Atezolizumab
  • Cohort 2
    • Participants who demonstrated durability of Clinical Benefit and Tumor Response to Atezolizumab

Clinical Trial Outcome Measures

Primary Measures

  • Time to loss of clinical benefit (TTLCB) from Atezolizumab treatment
    • Time Frame: Time from first dose to loss of clinical benefit as assessed by the treating physician, through the end of study (approximately 5 years).
  • Duration of response (DOR) to Atezolizumab treatment
    • Time Frame: Time from first documentation of complete response (CR) or partial response (PR), whichever occurs first, until progressive disease (PD), as evaluated by the physician according to routine practice or death; through the end of study (~ 5 years)

Secondary Measures

  • Disease control rate (DCR) of overall population
    • Time Frame: Percentage of patients who achieved a CR, a PR, or stable disease (SD) as evaluated by the physician according to clinical practice at the time of the fifth Atezolizumab infusion; (until the end of study, approximately 5 years)
  • Progression-free survival (PFS) of overall population
    • Time Frame: Time from initiation of study treatment to the first occurrence of progressive disease (PD) or death from any cause, whichever occurs first, as evaluated by the physician according to clinical practice, through the end of study (approximately 5 years)
  • Time to response (TTR) of overall population
    • Time Frame: Time from first dose to first response as assessed in clinical routine, through the end of study (approximately 5 years)
  • Overall response rate (ORR) of overall population
    • Time Frame: Rate of CR and PR in patients as assessed in clinical routine, through end of study (approximately 5 years)
  • Best overall response (BOR) of overall population
    • Time Frame: Best response achieved within 12 weeks as assessed in clinical routine, through the end of study (approximately 5 years)
  • Best overall response of patients in cohort 2 (“Coh2 BOR”)
    • Time Frame: Baseline through the end of study (approximately 5 years)
  • Overall survival of cohort 2 (“Coh2 OS”)
    • Time Frame: Time from initiation of Atezolizumab treatment to death from any cause (until the end of study, approximately 5 years).
  • Percentage of participants with Adverse Events (AEs)
    • Time Frame: Baseline through the end of study (approximately 5 years)

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of locally advanced or metastatic NSCLC (histologically or cytologically confirmed stage IIIB/stage IV) and prior chemotherapy – Decision to be treated with Atezolizumab according to Summary of Product Characteristics (SmPC) by treating physician, independent of this non-interventional study – No contraindication to treatment with Atezolizumab Retrospective Inclusion: – Participants may be included retrospectively. Retrospective inclusion and documentation is limited to up to 9 weeks after initial start of therapy with Atezolizumab (corresponding to a maximum of 3 treatment cycles with drug administrations at 3-week intervals), corresponding to a maximum of 9 weeks prior to date of informed consent. Quality of life for this population will be captured and assessed retrospectively with a modified questionnaire for the period immediately prior to treatment start until study inclusion. participants who started Atezolizumab therapy more than 9 weeks prior to ICF being obtained may not be included in the study. – Participants who give consent to be retrospectively enrolled but have already discontinued Atezolizumab for reasons such as loss of clinical benefit or toxicity may also take part in the study, given their first administration of Atezolizumab is within 9 weeks of consenting to take part, and they meet all other eligibility criteria. Exclusion Criteria:

Patients not eligible for Atezolizumab treatment according to SmPC

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hoffmann-La Roche
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Clinical Trials, Study Director, Hoffmann-La Roche

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.